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Abstract
Type 2 diabetes mellitus (T2DM) is a worldwide epidemic with considerable health and economic consequences. T2DM patients are often treated 
with more than one drug, including oral antidiabetic drugs (OAD) and drugs used to treat diabetic complications, such as dyslipidemia and hyperten-
sion. If genetic testing could be employed to predict treatment outcome, appropriate measures could be taken to treat T2DM more effi  ciently. Here 
we provide a review of pharmacogenetic studies focused on OAD and a role of common drug-metabolizing enzymes (DME) and drug-transporters 
(DT) variants in therapy outcomes. For example, genetic variations of several membrane transporters, including SLC22A1/2 and SLC47A1/2 genes, are 
implicated in the highly variable glycemic response to metformin, a fi rst-line drug used to treat newly diagnosed T2DM. Furthermore, cytochrome 
P450 (CYP) enzymes are implicated in variation of sulphonylurea and meglitinide metabolism. Additional variants related to drug target and diabe-
tes risk genes have been also linked to interindividual diff erences in the effi  cacy and toxicity of OAD. Thus, in addition to promoting safe and cost-ef-
fective individualized diabetes treatment, pharmacogenomics has a great potential to complement current eff orts to optimize treatment of diabetes 
and lead towards its eff ective and personalized care.
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It has been estimated that around 285 million peo-
ple suff er from type 2 diabetes mellitus (T2DM) 
with projected rise to 438 million in the next 20 
years (1). Current therapies for T2DM include life-
style modifi cation and use of oral antidiabetic 
drugs (OAD). Several OAD classes are currently 
available to treat T2DM patients, with sulphonylu-
reas (SU), biguanides, thiazolidinediones (TZDs), 
and meglitnides being the most frequently used. 
Eff ects of these drugs depend on the extent of 
drug absorption from the gut lumen, uptake and 
metabolism of the drug in the liver, the extent of 
its transport back into the systemic circulation for 
extrahepatic eff ects, and for drugs with substan-
tial renal secretory clearance (e.g., metformin) on 
active renal tubular secretion into the urine. Drug-
metabolizing enzymes (DME) and drug transport-
ers (DT) have a crucial role in the fate of drugs in 
human body. Information regarding the incidence 
of cytochrome P450 (CYP) gene polymorphisms is 
increasing (2-4), although the level of detail such 
as in the case of other DME, including UDP-glu-
curonosyltransferases and N-acetyltransferases, is 
not as extensive. In addition, recent studies identi-
fi ed genetic variations of DT associated with the 
altered treatment outcomes (5,6) and revealed an 
important role of the transporter-mediated OAD 
uptake in their disposition and eff ects (4).
Furthermore, recent data showed that epigenetic 
changes in response to environmental stimuli may 
play an important role in the diabetes develop-
ment (7). In addition to the role of DNA methyla-
tion and histone modifi cations, recent studies also 
indicated that microRNAs (miRNAs), a class of 
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small, single-stranded non-protein coding gene 
products that post-transcriptionally suppress 
mRNA target expression, could serve as a new 
generation of biomarkers for diabetes. Strikingly, a 
recent analysis of the specifi c miRNAs provided 
suffi  cient data to diagnose and predict the T2DM 
development in normoglycemic patients (8). Thus, 
characterization of the miRNAs pattern together 
with the analysis of specifi c pharmacogenetic vari-
ants could facilitate the design of a therapy tai-
lored to the individual patient, contributing to the 
current eff orts in the personalized medicine (9,10). 
Here we aim to summarize the pharmacogenom-
ics data related to the T2DM therapy, particularly 
the associations of SU, TZDs, biguanides, and meg-
litinides treatment outcomes with polymorphisms 
of DME, DT, drug target and diabetes risk genes 
that might lead to the promotion of personalized 
T2DM treatment.
Sulphonylureas
In addition to insulin resistance (IR), insuffi  cient 
pancreatic β-cell function plays an important role 
in the pathogenesis of T2DM. The insuffi  cient pro-
duction and secretion of insulin can be increased 
by secretagogue drugs, like SU that bind to sulpho-
nylurea receptor (SUR) leading to the cell depolari-
zation and stimulation of insulin release. Potassium 
inwardly rectifi er 6.2 subunit (Kir6.2) of pancreatic 
islet ATP-sensitive K+ (KATP) channels are het-
erooctamers assembled from Kir6.2 and the 
sulphonylurea receptor 1 (SUR1), encoded by the 
KCNJ11 and ABCC8 gene, respectively. This channel 
is essential for glucose-stimulated insulin secretion 
from pancreatic β-cells, modulates glucose uptake 
into skeletal muscle, glucose production and re-
lease from the liver (11). Physiologically, decreased 
plasma glucose levels lead to lower metabolic rate 
which opens KATP channels, suppressing electri-
cal activity and insulin release. In contrast, KATP 
channels close when metabolism increases, ATP 
rises and MgADP falls, leading to membrane de-
polarization, opening of voltage-gated Ca2+ chan-
nels, Ca2+ infl ux, and insulin secretion.
In recent years single nucleotide polymorphisms 
(SNPs) of the genes encoding KATP channel have 
been related to the effi  cacy of secretagogue drugs 
(Table 1). Loss-of-function (LOF) mutations of these 
genes are the most common cause of congenital 
hyperinsulinism, with over 150 mutations charac-
terized in SUR1 (ABCC8) and 24 in Kir6.2 (KCNJ11) 
(12). On the other hand, gain-of-function (GOF) 
mutations in Kir6.2 or SUR1 cause neonatal diabe-
tes (ND). A similar number of over 40 diff erent ND 
mutations have been characterized in Kir6.2 and 
in SUR1 (12). All Kir6.2 mutations cause dominant 
ND by reducing the ability of ATP to block KATP 
channel (13), hyperpolarizing the β-cells, and pre-
venting insulin secretion. Thus, the mutated KATP 
channel does not close in response to increased 
ATP concentrations. However, it could be closed 
when SU bind to SUR1 by an ATP-independent 
route. The discovery of the causal role of KATP 
channels has enabled ND patients to switch from 
insulin to SU therapy that signifi cantly improved 
glycemic control and reduced the risk of diabetic 
complications (14,15).
A common Glu23Lys polymorphism (also known 
as E23K) in KCNJ11 (potassium inwardly-rectifying 
channel, subfamily J, member 11) gene encoding 
Kir6.2, is associated with T2DM development 
(16,17), as well as an increased risk of SU therapeu-
tic failure (18). The functional eff ects of the E23K 
variant on insulin secretion and insulin sensitivity 
in humans are controversial, although recent larg-
er studies demonstrate a signifi cantly reduced in-
sulin secretion, lower insulin levels, and improved 
insulin sensitivity (19), consistent with enhanced 
KATP activity in pancreatic β-cells. Furthermore, a 
recent study found that the carriers of the KCNJ11 
K-allele had better therapeutic response to gli-
clazide (20). KCNJ11 variations have been also asso-
ciated with altered response to glibenclamide 
therapy and misdiagnosis of Type 1 diabetes (14). 
Importantly, recent evidence demonstrated that 
patients with KCNJ11 mutations could be treated 
more effi  ciently with SU than with insulin 
(14,21,22).
The ABCC8 gene encodes the SUR1 subunit which 
regulates KATP channel activity. ABCC8 mutations 
are genetically more heterogeneous, with ho-
mozygous, heterozygous and compound hetero-
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T2DM patients (N = 525) with 
secondary SU failure.
Carriers of the K allele showed a tendency toward shorter 
duration of therapy before failure as compared with EE 
homozygotes; pancreatic islets from K allele carriers showed 
a signifi cantly lower glibenclamide-stimulated insulin release.
Sesti et al, 
2006 (18)
Patients with T2DM (N = 101) 
treated with gliclazide for 6 months.
K-allele carriers had signifi cantly higher decrease in HbA1c 
compared with EE homozygotes.
Javorsky et al, 
2012 (20)
3p + 215 G>A
(rs5210)
Patients with T2DM (N = 1.268), 8 
weeks of gliclazide therapy.





Patients with T2DM (N = 1.268), 8 
weeks of gliclazide therapy.




Patients with T2DM (N = 228) on SU 
therapy.
Carriers of wild-type CC genotype had signifi cantly lower 
HbA1c compared to the patients with TT genotype. 




Patients with T2DM (N = 228) on SU 
therapy.
Patients with wild-type GG genotype had signifi cantly
higher HbA1c levels compared to the patients with AA 
genotype.
Nikolac et al, 
2009 (28)
Patients with T2DM (N = 251) on SU 
therapy.
Patients with GG genotype had signifi cantly higher 
triglyceride levels compared to the patients with AA 
genotype.
Nikolac et al, 
2012 (29)
KCNQ1
rs163184 T>G T2DM patients (N = 87) who failed 
to achieve glycemic control on 
metformin therapy, treated 6 
months with SU.
Carriers of the T-allele (TT+TG) achieved signifi cantly lower 





rs7903146 C>T T2DM patients (N = 87) 6-month 
sulphonylurea in addition to 
metformin.
Signifi cantly higher reduction in HbA1c and FPG in patients 
with CC genotype compared to the CT+TT genotype.
Schroner et 
al, 2011 (39)
T2DM patients (N = 189), 6-month 
SU treatment.
T allele was signifi cantly more frequent in patients who 
failed to respond to SU than in the control subjects.




Population-based GoDARTS study: 
T2DM patients, incident SU users 
(N = 901).
2-fold greater likelihood of SU failure (not to achieve 
target HbA1c<7% (53 mmol/mol)) in the 12% of the TT 
homozygotes at rs1225372 than in the GG group.





Healthy volunteers (N = 21), a single 
oral dose of glyburide.
In *3/*3 homozygotes total drug clearance was less than 
half, while insulin secretion was higher as compared to the 
wild-type *1/*1 genotype.
Kirchheiner et 
al, 2002 (48) 
Healthy volunteers (N = 29). In *3 allele heterozygotes higher the median total AUC of 
glyburide and glimepiride, compared to subjects with the 
*1/*1 genotype.
Niemi et al, 
2002 (49)
A population-based cohort 
Rotterdam Study (N = 7.983).
Carriers of *3 allele required lower doses of tolbutamide to 
regulate glucose levels as compared to the *1/*1 genotype.






Population-based GoDARTS study: 
T2D patients, incident users of SU 
(N = 1.073).
More likely to achieve a treatment HbA1c<7% (53 mmol/
mol) than patients with the wild-type genotype.
Zhou et al, 
2010 (51)
FPG - fasting plasma glucose; AUC - area under the curve.
TABLE 1. Summary of the gene polymorphisms involved in the pharmacogenetics of sulphonylureas.
http://dx.doi.org/10.11613/BM.2013.020 Biochemia Medica 2013;23(2):154–71
  157
Semiz S. et al. Pharmacogenetics of oral antidiabetics
zygous mutations being described (23). Hetero-
zygous activating mutations in the ABCC8 gene 
have been characterized as a cause of permanent 
and transient ND that may present as T2DM (24). 
Interestingly, a common Ser1369Ala SNP of ABCC8 
infl uenced antidiabetic effi  cacy of SU in Chinese 
(25), but not in German population (26). In addi-
tion, this same Ser1369Ala variant of ABCC8 ap-
peared not to be associated with the risk for severe 
SU-induced hypoglycemia in German (26) and Jap-
anese (27) T2DM patients. Additional polymor-
phisms of ABCC8 gene, including SNP in exon 16 
(-3C/T) and exon 31 (Arg1273Arg) have been also 
reported to be associated with the SU effi  cacy in 
European Caucasians (28-30).
Importantly, two common ATP-sensitive potassi-
um (KATP) channel variants, E23K and S1369A, of 
the KCNJ11 and ABCC8 genes respectively, are in 
strong linkage disequilibrium (LD) and form a hap-
lotype that appears to be associated with an in-
creased T2DM risk (31). A recent analysis of struc-
ture-activity relationships in KATP channels con-
taining either the E23/S1369 non-risk or K23/A1369 
risk haplotypes, demonstrated that KATP channels 
containing the K23/A1369 risk haplotype were sig-
nifi cantly less sensitive to inhibition by tolbuta-
mide, chlorpropamide, and glimepiride (32). Glib-
enclamide and glipizide demonstrated similar in-
hibitory eff ects on KATP channels in patients with 
either haplotype. Based on these data, the authors 
suggested that it would be possible to design nov-
el OAD with an increased effi  cacy in patients ho-
mozygous for these common KATP channel haplo-
types.
Patients with defi cient hepatic nuclear factor-1-
-alpha (HNF1-alpha), a transcription factor vital for 
correct β-cell development and function, have 
progressive β-cell deterioration and are more sen-
sitive to SU than matched T2DM patients (33). Fur-
thermore, a recent study has suggested that the 
magnitude of fasting plasma glucose (FPG) levels 
reduction after 6-month SU treatment in addition 
to metformin in T2DM patients was related to the 
rs163184 (T>G) SNP in KCNQ1 gene (34). KCNQ1 en-
codes a voltage-gated potassium channel ex-
pressed in the heart, stomach, small and large in-
testine, kidney, and pancreas. However, its role in 
insulin secretion by pancreatic β-cells is not com-
pletely understood. Importantly, the FPG response 
to SU was signifi cantly lower in carriers of the risk 
GG genotype of rs163184 variation in KCNQ1 (34). 
In addition, the Arg(972) variant of IRS-1 gene en-
coding the insulin receptor substrate (IRS)-1 that is 
an important component of the insulin signaling 
cascade, was also associated with an increased risk 
for secondary SU failure (35).
The most promising gene variants aff ecting the SU 
response are those involved in drug pharmacody-
namics, such as the transcription factor 7-like 2 
(TCF7L2) that encodes a transcription factor (Tcf-4), 
involved in the regulation of cellular proliferation 
and diff erentiation (36). TCF7L2 gene has the 
strongest association with T2DM reported to date 
(37,38). A recent study demonstrated that the de-
gree of reduction in HbA1c and FPG levels follow-
ing a combined SU and metformin treatment was 
related to TCF7L2 rs7903146 (C>T) SNP (39). Inter-
estingly, individuals with the T2DM-associated ho-
mozygous TT genotype were less likely to respond 
to SU therapy (39-41).
Sulphonylureas are mainly metabolized by the en-
zyme cytochrome P450 (CYP) isoform CYP2C9. A 
recent population-based Rotterdam study showed 
that polymorphisms in CYP2C9 gene aff ected the 
patient sensitivity to SU (42). The carriers of 
CYP2C9*3 (Ile359Leu) polymorphism appeared to 
be protected against development of T2DM (43), 
while CYP2C9*2 (Arg144Cys) polymorphism was 
not associated with diabetes susceptibility (44). Al-
though these two allelic variants, CYP2C9*2 and 
CYP2C9*3, have been associated with elevated SU 
serum levels, the tolbutamide dose was lower in 
CYP2C9*3 allele carriers as compared to patients 
with the wild-type CYP2C9 genotype, while similar 
eff ect was not observed for the CYP2C9*2 geno-
type (42). Furthermore, CYP2C9*3 increased the risk 
of hypoglycemia in T2DM patients treated with SU 
(43,45) and multiple studies indicated that the 
CYP2C9*3 allele was associated with decreased SU 
clearance (46,47). Homozygous carriers of the 
CYP2C9*3/*3 genotypes had reduced clearance of 
glyburide and increased insulin secretion follow-
ing glyburide administration (48, 49). Furthermore, 
diabetic patients with a CYP2C9*3 variant required 
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lower doses of tolbutamide for glucose control 
than patients with the wild-type genotype (42). 
Recently, Swen et al. (50) demonstrated no signifi -
cant eff ects of the CYP2C9*2 and CYP2C9*3 alleles 
on prescribed dose in incident SU users. However, 
a large population-based GoDARTS (Genetics of 
Diabetes Audit and Research in Tayside Scotland) 
study performed in 1,073 incident SU users dem-
onstrated that patients with two copies of the *2 
or *3 alleles were three times more likely to achieve 
treatment target of HbA1C levels under 7% (53 
mmol/mol) than patients with two wild-type 
CYP2C9*1 alleles (51).
Thiazolidinediones
Thiazolidinediones, also known as glitazones, act 
by activating their molecular target, PPARs (peroxi-
some proliferator-activated receptors). TZDs bind 
with greatest specifi city for PPARγ, a nuclear tran-
scription factor expressed diff usely in humans, in-
cluding adipocytes, to promote adipogenesis and 
fatty acid uptake. By reducing circulating fatty acid 
concentrations and lipid availability in liver and 
muscle, these drugs improve the patients’ sensitiv-
ity to insulin and reduce hyperglycemia. In addi-
tion, TZDs have a multitude of other therapeutic 
eff ects including anti-infl ammatory eff ects and 
amelioration of hypertension, microalbuminuria 
and hepatic steatosis (52).
Rosiglitazone and pioglitazone are TZDs that have 
been shown to improve glycemic control and may 
act to slow the progression of β-cell failure. How-
ever, recent studies demonstrated that use of ros-
iglitazone could cause serious side eff ects, includ-
ing an increased risk of myocardial infarction and 
death from cardiovascular causes as compared to 
pioglitazone (53,54). Due to these serious side ef-
fects, the European Medicines Agency (EMA) has 
recommended the suspension of the marketing 
authorizations for the rosiglitazone, while US Food 
and Drug Administration (FDA) has decided that 
rosiglitazone can remain available, but only under 
a very stringent restricted access program. Thus, 
the only TZD that is still available on market is pi-
oglitazone, which appears to have more favorable 
eff ects on cardiovascular system in T2DM patients 
as compared to rosiglitazone (55,56). The mecha-
nism of the antidiabetic action of pioglitazone in-
volves activation of PPARγ, while its direct antioxi-
dant action may also contribute to its eff ect on IR 
(57). However, the treatment with pioglitazone for 
more than one year may be associated with an in-
creased risk of bladder cancer (58-60).
Recently, as shown in Table 2, several gene variants 
have been also associated with the TZDs therapy 
outcomes (61). Adipokinins, including adiponectin, 
leptin, resistin, peroxisome proliferator-activated 
receptor γ (PPARγ) and tumor necrosis factor 
(TNF)-α, are of a particular interest due to their im-
portant role in IR. Loss-of-function mutations in 
PPARγ are associated with severe IR and diabetes 
mellitus (62). Variants in PPARG or ADIPOQ (adi-
ponectin) have been variably associated with TZDs 
response. Strikingly, rosiglitazone was signifi cantly 
more eff ective in diabetic patients with Pro12Ala 
polymorphism of PPARG, who consequently had a 
signifi cantly greater decrease in FPG and HbA1c 
levels than carriers of the wild-type genotype (63). 
A recent study reported that Thr394Thr and 
Gly482Ser SNPs of the peroxisome proliferator ac-
tivated receptor-γ coactivator-1α (PGC-1α), which is 
a transcriptional coactivator of PPARγ, were also 
associated with rosiglitazone effi  cacy in Chinese 
T2DM patients (64). In addition, a pilot study sug-
gested that the G/G genotype of resistin SNP-420 
may be an independent predictor of the reduction 
of FPG and HOMA-IR (Homeostasis Model of As-
sessment-Insulin Resistance) by pioglitazone (65). 
Furthermore, recent studies demonstrated that 
the genetic variations of –11377C/G and T45G in 
adiponectin gene (66) and leptin G-2548A (67), as 
well as TNF-α G-308A (67) appeared to aff ect ros-
iglitazone effi  cacy and reversed IR in Chinese dia-
betic patients.
Treatment with TZDs has been particularly associ-
ated with high rates of developing fl uid retention 
and peripheral edema, leading to congestive heart 
failure (52). Interestingly, a recent study done by 
Chang et al. (68) have suggested that rs296766 
polymorphism of AQP2 gene coding aquaporin-2 
(the vasopressin-regulated water channel), and 
rs12904216 polymorphism of SLC12A1 (the solute 
carrier protein family 12 group A, member one) 
gene coding the sodium-potassium-2 chloride 
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Patients with T2DM (N = 198), 
12-week rosiglitazone therapy.
The decrease in FPG and HbA1c levels was signifi cantly 
greater in subjects with the Pro12Ala genotype, who had a 
signifi cantly better drug response.









Patients with T2DM (N = 41), 
12-week rosiglitazone therapy.
Patients with the A or Ser variant were more likely to have a 
negative response; patients with Gly482Gly genotype had 
decreased FPG and PINS to a greater degree compared with 
Gly482Ser + Ser482Ser genotype.





Prospective study: T2DM patients 
treated with pioglitazone (N = 121)
Retrospective study: T2DM patients 
treated with pioglitazone (N = 63)
The reduction of HbA1c correlated with the G/G genotype. Makino et 







Patients with T2DM (N = 42) treated 
12 weeks with rosiglitazone.
Attenuated eff ect in -11377CG +GG heterozygotes on FPG, 
PPG, HOMA-IR compared with CC genotype; enhanced eff ect 
in patients with -11377/45 CGTT diplotype on FPG and PPG.





Patients with T2DM (N = 42) treated 
12 weeks with rosiglitazone.
Patients with G allele had signifi cantly lower BMI and serum 
leptin levels and increased FPG than patients with AA 
genotype.





Patients with T2DM (N = 42) treated 
12 weeks with rosiglitazone.
Attenuated eff ect in patients with GA+AA genotype on FINS 
compared with GG genotype.






Healthy volunteers (N = 31); a 
single-dose rosiglitazone.
Decreased mean total clearance, elimination half-lives, 
and plasma glucose AUC; *3 allele confers higher in vivo 
metabolic capacity than the wild-type *1 allele.
Kirchheiner 
et al, 2006 
(71)
FPG - fasting plasma glucose; PINS - postprandial insulin; PPG - postprandial glucose; HOMA-IR - homeostasis model of assessment - insulin 
resistance; BMI - body mass index; FINS - fasting insulin; AUC - area under the curve.
TABLE 2. Summary of the gene polymorphisms involved in the pharmacogenetics of thiazolidinediones.
transporter (NKCC2) with a key role in electrolyte 
movement across epithelia, represented risk fac-
tors for TZDs-associated edema. In addition to 
these genetic factors, the same study demonstrat-
ed that female gender and older age were also 
contributing factors to the edema development 
following TZDs treatment.
A recent study showed a diminished eff ect of pi-
oglitazone treatment on glycemic control in pa-
tients with Ser447X polymorphism of gene encod-
ing lipoprotein lipase (LPL), the enzyme responsi-
ble for the lipolytic processing of triglyceride-rich 
lipoproteins (61). CYP2C8 and CYP3A4 are the main 
DME catalyzing biotransformation of the pioglita-
zone (69), whereas rosiglitazone is metabolized by 
CYP2C8 and CYP2C9 (70). Genetic variation in 
CYP2C8 was found to be associated with altered 
clearance of rosiglitazone, with higher drug clear-
ance in carriers of CYP2C8*3 allele coding for Arg139-
Lys and Lys399Arg amino acid substitutions (71).
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Biguanides
The biguanide drug metformin is recommended 
as the fi rst-line therapy for T2DM (72). A main ac-
tion of metformin is suppression of hepatic gluco-
neogenesis (73). Other antihyperglycemic eff ects 
include an increase of glucose uptake and utiliza-
tion, improvement of insulin sensitivity, and reduc-
tion of intestinal glucose absorption (73). The mo-
lecular mechanisms of metformin action are not 
fully elucidated. It is believed that metformin in-
creases the AMP/ATP ratio by specifi c inhibition of 
mitochondrial respiratory-chain complex 1, which 
leads to the activation of adenosine monophos-
phate-activated protein kinase (AMPK) (74-77). Po-
tential mechanism of AMPK phosphorylation by 
metformin includes the upstream serine-threo-
nine kinase11 (STK11/LKB1) (78). However, a recent 
study showed that metformin could also inhibit 
gluconeogenesis in an AMPK-independent way 
(79).
Metformin is not metabolized but is excreted un-
changed in urine by active tubular secretion (80). 
There is large variation in metformin renal clear-
ance, and genetic factors contribute to this by 
more than 90% (81,82). Its oral absorption, hepatic 
uptake and renal elimination are mediated by car-
rier proteins (83). The intestinal absorption of met-
formin is probably mediated by plasma membrane 
monoamine transporter (PMAT, encoded by 
SLC29A4 gene), expressed on the luminal side of 
enterocytes (84). Organic cation transporter 1 
(OCT1, encoded by SLC22A1 gene), expressed in 
the basolateral membrane of hepatocytes, medi-
ates hepatic metformin uptake (85). OCT2 (encod-
ed by SLC22A2), expressed primarily at the basola-
teral membrane in the kidney tubular cells, facili-
tates uptake of metformin into proximal tubule 
cells (86). The multidrug and toxin extrusion trans-
porter 1 (MATE1, encoded by SLC47A1) and MATE2-K 
(encoded by SLC47A2), located in the apical mem-
brane of the renal proximal tubule cells, facilitate 
metformin excretion from tubular cells into urine 
(87-89).
The therapeutic response to metformin is highly 
variable. In patients receiving metformin as an ini-
tial treatment for T2DM, less than two-thirds 
achieve desired glycemic control or the HbA1c goal 
of < 7% (< 53 mmol/mol) (90). This implies that 
identifi cation of genetic factors associated with 
treatment eff ectiveness could be relevant. The ma-
jority of pharmacogenetic studies of metformin 
response have investigated the eff ects of polymor-
phisms in the gene encoding OCT1, SLC22A1 (Table 
3). OCT1 is necessary for metformin transport into 
the liver and subsequent metformin activity. Hu-
man SLC22A1 gene is highly polymorphic. Re-
duced-function polymorphisms of the SLC22A1 
gene, such as R61C (rs12208357), G401S 
(rs34130495), 420del (rs72552763), and G465R 
(rs34059508) have been associated with lower ef-
fects of metformin in the oral glucose tolerance 
test (91). These same SNPs were also associated 
with a signifi cantly higher metformin AUC, higher 
maximal plasma concentration and lower oral vol-
ume of distribution (92). However, a subsequent 
study demonstrated an additive increase in renal 
clearance of metformin with increasing number of 
reduced-function alleles (93). In a large popula-
tion-based GoDARTS study the eff ects of R61C and 
420del variants on initial glycemic response to 
metformin, the mid-term HbA1c control, and the 
rate of metformin monotherapy failure were not 
found (94). Another study analyzed the eff ects of 
11 tagging SNPs in the SLC22A1 gene on HbA1c re-
duction, in a smaller cohort of incident users of 
metformin (95). A signifi cant association of intronic 
rs622342 A>C SNP and lower HbA1c reduction was 
found (95).
A recent prospective study investigated the eff ects 
of variations in genes encoding OCT1, OCT2, 
MATE1, MATE2, and PMAT, on the trough steady-
state plasma concentration (Css) of metformin and 
HbA1c change in T2DM patients treated with met-
formin (96). The mean trough Css of metformin, as 
well as the absolute decrease in HbA1c levels after 
6 and 24 months, correlated conversely with the 
number of reduced-function SLC22A1 alleles (R61C, 
G401S, M420del and G465R) (96). It is hypothesized 
that in patients with reduced function OCT1 vari-
ants, less metformin is transported into hepato-
cytes and the volume of distribution decreases, re-
sulting in a shorter half-life and lower trough Css 
of metformin (96). These results are in accordance 
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Healthy volunteers (N = 21). Lower eff ects of metformin in the oral glucose 
tolerance test.
Shu et al, 
2007 (91)
Healthy volunteers (N = 20). Higher metformin AUC, higher maximal 
plasma concentration and lower oral volume of 
distribution.
Shu et al, 
2008 (92)
Healthy men (N = 103). Additive increase in renal clearance of 




Prospective study: T2DM 
patients treated with 
metformin (N = 159).
Inverse correlation of metformin trough Css and 
reduction of HbA1c levels with the number of 
reduced-function SLC22A1 alleles.
Christensen 





study: T2DM patients, incident 
users of metformin (N = 1.531).
No eff ects on initial glycemic response to 
metformin, the mid-term HbA1c control, and the 
rate of metformin monotherapy failure.
Zhou et al, 
2009 (94)
rs622342 A>C Population-based study: T2DM 
patients, incident users of 
metformin (N = 102).







Healthy subjects (N = 26). Increased metformin Cmax and AUC and 
reduced renal clearance of metformin.
Song et al, 
2008 (100)
A270S (Ala270Ser) (rs316019) Healthy subjects (N = 15). Reduced renal clearance of metformin. Wang et al, 
2008 (101)
Healthy subjects (N = 23). Increased metformin renal clearance. Chen et al, 
2009 (102)
SLC47A1
rs2289669 G>A Population-based study: T2DM 
patients, incident users of 
metformin (N = 116).
Greater reduction of HbA1c levels. Becker et al, 
2009 (103)
rs8065082 C>T DPP study: individulas at high 
risk for T2DM randomized 
to placebo (N = 1.000), 
metformin (N = 990) or lifestyle 
intervention program (N = 
1.004).
Lower diabetes incidence in subjects treated 
with metformin.
Jablonski 
et al, 2010 
(104)
SLC47A2
rs12943590 G>A Retrospective study: T2DM 
patients initially treated with 
metformin (N = 253).
Lower HbA1c reduction. Choi et al, 
2011 (105)
ATM
rs11212617 A>C GWA study (N = 1.024) and two 
replication cohorts (N = 1.783 
and N = 1.113) of T2D patients, 
incident users of metformin.
Association with treatment success (achieving 
an HbA1c below 7% (53 mmol/mol)), the 
combined odds ratio = 1.35.
Zhou et al, 
2011 (107)
AUC - area under the curve; Css - steady-state plasma concentration; Cmax – peak plasma concentration.
TABLE 3. Summary of the gene polymorphisms involved in the pharmacogenetics of biguanides.
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with previous studies (91,93). Replication of results 
regarding infl uence of OCT1 low-activity alleles on 
metformin pharmacokinetics and response, indi-
cated that those variants could be useful pharma-
cogenetic markers for metformin therapy.
The fi rst study on the association of genetic varia-
tions of OCT1, OCT2, and MATE1 transporters with 
gastrointestinal side eff ects of metformin therapy 
has been recently published (97). The minor alleles 
of rs628031 (M408V) and rs36056065 (8 bp inser-
tion), which are two variants of the SLC22A1 gene 
in strong LD, were signifi cantly associated with the 
presence of side eff ects (97). The local increase of 
drug concentration in the intestinal tissue is pro-
posed as a mechanism of metformin intolerance 
(98). OCT1 and OCT3 (encoded by SLC22A3 gene) 
are also expressed in enterocytes (99), and al-
though their role in the intestinal transport of met-
formin is not yet defi ned, authors suggest that 
SNPs in these genes may infl uence the intestinal 
metformin uptake and thus induce gastrointesti-
nal side eff ects (97).
The results of the studies exploring the eff ect of 
the only common coding variant in the gene en-
coding OCT2 (SLC22A2), A270S (rs316019), on met-
formin clearance, have been contradictory. Two 
studies found signifi cantly reduced renal clearance 
of metformin in homozygous variant carriers com-
pared to wild-type homozygotes (100,101). Inter-
estingly, a separate study reported the opposite 
eff ect in individuals heterozygous for A270S vari-
ant who had higher metformin renal clearance as 
compared to the reference group (102). Chris-
tensen et al. (96) did not fi nd the association be-
tween A270S and metformin trough Css or thera-
peutic response. However, given the importance 
of OCT2 in metformin pharmacokinetics, further 
pharmacogenetic studies are needed.
A preliminary study in the incident metformin us-
ers from the population-based Rotterdam study 
cohort assessed the infl uence of variations in 
MATE1-encoding gene, SLC47A1, on the HbA1c-low-
ering eff ect of metformin (103). From 12 tagging 
SNPs analyzed, the rs2289669 G>A in intron 10 was 
associated with greater reduction in HbA1c levels 
(103). In a latter large-scale prospective clinical 
study (Diabetes Prevention Program, DPP) an asso-
ciation of rs8065082 SNP in the SLC47A1 gene and 
lower diabetes incidence in subjects treated with 
metformin was found (104). This SNP was in high 
LD with rs2289669 G>A and thus, the DPP study 
confi rmed the fi ndings from a small preliminary 
study of Becker et al. (103). However, rs2289669 
G>A was not associated with metformin renal 
clearance (93), nor with metformin trough Css (96), 
and the mechanism underlying the impact of this 
SLC47A1 SNP remained unclear.
A recent study analyzed the eff ect of the MATE2-K 
gene (SLC47A2) polymorphism on glycemic re-
sponse to metformin in newly diagnosed T2DM 
patients (105). A common 5’-UTR variant, g.-130-
G>A (rs12943590), was associated with enhanced 
promoter activity and weaker response to met-
formin, assessed by the relative HbA1c change 
(105). The study also explored the impact of OCT1, 
OCT2, and MATE1 variants on the initial metformin 
response. In line with previous studies (103,104), 
the intronic rs2289669 G>A SNP in MATE1 gene 
was associated with higher HbA1c relative change, 
almost at the level of statistical signifi cance (105).
In addition, other candidate genes which are likely 
to modulate metformin pharmacokinetics and re-
sponse are genes encoding OCT3 (SLC22A3) and 
PMAT (SLC29A4) transporters. Recent in vitro study 
suggested that OCT3 is implicated in the uptake of 
metformin in muscle cells and its genetic variants 
may modulate metformin action (106). Genetic 
polymorphisms in PMAT showed a tendency of as-
sociation with lower metformin trough concentra-
tion, and could be associated with decreased met-
formin absorption (96).
Recently, the fi rst genome-wide association study 
(GWAS) on glycemic response to metformin in 
T2DM was performed. The study identifi ed a com-
mon rs11212617 A>C SNP associated with treat-
ment success in the large GWAS cohort (107), 
which was replicated in the two additional cohorts 
(107). The authors proposed that ATM (the ataxia 
telangiectasia mutated) gene, encoding a serine/
threonine protein kinase of the phosphoinositide 
3-kinase-related protein kinase (PIKK) family, was 
the causative gene due to its association with IR, 
increased T2DM risk, and its role in AMPK activa-
tion (107). In general, additional studies are re-
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quired to identify genes involved in mechanisms 
of metformin pharmacological action.
Meglitinides
This class of short-acting insulin secretagogues 
acts by binding to β-cells and inhibiting KATP 
channel to stimulate insulin release. This is similar 
to the mechanism of action of the sulphonylureas 
and both, meglitinides (glinides) and SU, bind at 
two sites of the SUR1 subunit to inhibit channel ac-
tivity (108). These two sites are thought to overlap 
to accommodate the negative charge and the cen-
tral phenyl ring present in both, SU and megliti-
nides (109). Repaglinide is specifi cally designed to 
stimulate early insulin secretion in the postprandi-
al period after binding to a distinct site on the 
β-cell (110). Similarly, nateglinide is an amino acid 
derivative that also induces an early insulin re-
sponse to meals decreasing postprandial blood 
glucose levels. Due to their short action, megliti-
nides have a lower risk to induce hypoglycemia 
than SU. Furthermore, meglitinides off er an alter-
native OAD agent of similar potency to metformin, 
and may be indicated where side eff ects of met-
formin are intolerable or where metformin is con-
traindicated.
Gene polymorphisms associated with the variable 
meglitinides response are summarized in Table 4. 
A recent study showed that SLCO1B1 gene, which 
encodes the organic anion-transporting polypep-
tide 1B1 (OATP1B1), is a major determinant that 
markedly aff ects the repaglinide pharmacokinet-
ics (111), consistent with an enhanced hepatic up-
take by OATP1B1. SLCO1B1 521T>C SNP appeared 
to play an important role in the nateglinide phar-
macokinetics (112). However, a study done by Ka-
lliokoski et al. (113) found that, in contrast to repa-
glinide, the nateglinide disposition was not aff ect-
ed by the SLCO1B1 521T>C SNP. Furthermore, the 
same research group demonstrated that the 
SLCO1B1*1B/*1B genotype was associated with re-
duced plasma levels of repaglinide, but had limit-
ed eff ects on the nateglinide disposition (114). A 
very recent study performed in healthy Chinese 
population have demonstrated that both, the 
521T>C SNP of SLCO1B1 and CYP2C9*3 polymor-
phism, could signifi cantly aff ect the nateglinide 
pharmacokinetics (115). However, these variants 
were not signifi cantly associated with variations in 
its glucose-lowering eff ects and could only partial-
ly explain the interindividual variability of nategli-
nide plasma concentration (115).
Nateglinide is metabolized by CYP2C9 and moder-
ate dose adjustments based on CYP2C9 genotypes 
may aff ect its pharmacokinetics (115) and interin-
dividual variability in its antihyperglycemic eff ects 
(70). Repaglinide is metabolized by CYP2C8 and 
CYP3A4 (116) and, according to clinical studies, 
CYP2C8*3 carriers have higher clearance than carri-
ers of the wild-type genotypes (70). However, re-
cent study demonstrated that CYP2C8*3 did not 
appear to aff ect the repaglinide pharmacokinetics 
(117).
A recent pharmacogenetic study done in the Chi-
nese population showed that the G2677T/A SNPs 
of MDR1 gene, encoding P-glycoprotein transport-
er, were associated with the variability in the repa-
glinide pharmacokinetics, suggesting that carriers 
of the MDR1 2677GT and TT allele might be ex-
posed to higher levels of repaglinide (118).
Furthermore, Dai et al. (119) found that rs2237892 
(C>T) and rs2237895 (C>A) SNPs, both located in 
intron 15 of KCNQ1 gene (120), encoding a voltage-
gated K+channel expressed in the various tissues 
including pancreas, were associated with the repa-
glinide effi  cacy in Chinese T2DM patients. Diabetic 
patients carrying the rs2237892 risk C allele had 
lower fasting insulin levels and HOMA-IR than 
those carrying the T allele. Furthermore, FPG and 
HOMA-IR levels were higher in T2DM patients with 
the rs2237895 risk C allele compared with the car-
riers of the A allele. Interestingly, following repagli-
nide treatment, T2DM patients with the rs2237892 
T allele and the rs2237895 C allele were more likely 
to have a positive eff ect on postprandial glucose 
levels than patients with the rs2237892 CC and 
rs2237895 AA genotype (119). In addition, a recent 
study performed by Yu et al. (121) demonstrated 
that Chinese T2DM patients, who were rs2237892 
TT homozygotes, had lower glucose levels follow-
ing repaglinide treatment, while the rs2237895 C 
risk allele in those patients was associated with 
greater increments in both, fasting insulin and HO-
MA-IR levels.
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Healthy volunteers (N = 17); a 
single-dose of nateglinide.
The Cmax and AUC of nateglinide were higher in the 
subjects with the TC and CC genotype compared to the TT 
genotype; the t1/2 of nateglinide in CC subjects was longer 
than in subjects with TT genotype.
Zhang et al, 
2006 (112)
Healthy volunteers (N = 31); a 
single-dose of nateglinide.
Signifi cant predictor of the AUC of nateglinide (a combined 
eff ect with the CYP2C9*3).
Cheng et al, 
2012 (115)
Healthy volunteers in two 
studies (N = 12) and (N = 32); a 
single-dose of repaglinide.
AUC of repaglinide was larger in participants with the CC 
genotype than in those with the TT genotype.
Kalliokoski 







Patients with T2DM (N = 
48) treated 8 weeks with 
repaglinide.
Better response on FINS and PINS in patients with 
rs13266634 CT+TT genotypes compared with CC genotype. 
In patients with rs16889462 GA genotype an enhanced 
repaglinide effi  cacy on FPG, PPG, and HbA1c compared with 
GG genotype.






Healthy volunteers (N = 24); a 
single-dose of repaglinide.
AUC of repaglinide was signifi cantly higher in subjects 
with the GT and TT alleles than in those with the GG and TA 
alleles.





Patients with T2DM (N = 
40) treated 8 weeks with 
repaglinide.
T2DM patients with the rs2237892 T allele and rs2237895 C 
allele were more likely to have a positive response in terms 
of PPG levels than T2DM patients with the rs2237892 CC and 
rs2237895 AA genotypes.
Dai et al, 
2012 (119)
Patients with T2DM (N = 
209) treated 8 weeks with 
repaglinide.
rs2237892 TT homozygotes exhibited lower 2-h glucose 
levels than the C allele carriers; rs2237892 C and rs2237895 
C alleles were associated with larger increase in FINS and 
HOMA-IR.





Patients with T2DM (N = 
40) treated 8 weeks with 
repaglinide.
Patients with the GA or AA genotype showed higher levels 
of FPG, PPG, and HbA1c compared with patients with GG 
genotype.
Yu et al, 
2010 (123)
TCF7L2
rs290487 C>T Patients with T2DM (N = 
40) treated 8 weeks with 
repaglinide.
In patients with the TT genotype, a better effi  cacy with 
respect to FINS, triglycerides, and LDL-c compared to the CC 
or CT genotype.





Patients with T2DM (N = 
35) treated 8 weeks with 
repaglinide.
The elevated PINS in patients with CT genotypes of -3186 C/T 
were signifi cantly lower than that in patients with the CC and 
TT genotypes.





Healthy volunteers (N = 31); a 
single-dose of nateglinide.
Signifi cant predictor of the AUC of nateglinide (a combined 
eff ect with the SLCO1B1 521T>C).
Cheng et al, 
2012 (115)
Cmax – maximum plasma concentration; AUC - area under the curve; t1/2 - elimination half-life; FINS - fasting insulin; PINS - postprandial insulin; 
FPG - fasting plasma glucose; PPG - postprandial glucose; HOMA-IR - homeostasis model of assessment - insulin resistance; LDL-c - low-density 
lipoprotein cholesterol.
TABLE 4. Summary of the gene polymorphisms involved in the pharmacogenetics of meglitinides.
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Polymorphisms of the zinc transporter solute car-
rier family 30 member 8 gene (SLC30A8), including 
rs13266634 (973C>T, Arg325Trp) and rs16889462 
(974G>A, Arg325Gln) SNPs, were recently reported 
to be related to T2DM development and impor-
tantly, to the repaglinide effi  cacy in Chinese T2DM 
patients (122). Patients with rs13266634 CT+TT 
genotypes showed decreased fasting and post-
prandial insulin levels compared to patients with 
CC genotype, while a signifi cant diff erences in the 
decreased fasting and postprandial glucose and 
HbA1c levels were found between T2DM patients 
with GA and GG genotype of SLC30A8 rs16888462 
SNP. Since SLC30A8 is mainly expressed in the pan-
creatic β-cells and appears to play a critical role 
during insulin maturation and release, the authors 
have speculated that SLC30A8 variations infl uence 
the zinc disposition and that KATP function, aff ect-
ing the therapeutic effi  cacy of repaglinide (122).
Furthermore, the KCNJ11 and TCF7L2 polymor-
phisms seemed also to be associated with repagli-
nide effi  cacy in Chinese T2DM patients (123). Dia-
betic patients with the GA or AA genotype of the 
KCNJ11 Lys23Glu SNP showed higher levels of fast-
ing and postprandial glucose and HbA1c following 
repaglinide treatment than in patients with the GG 
genotype. On the other hand, in T2DM patients 
with the TT genotype of TCF7L2 rs290487 (C/T), 
the drug showed better effi  cacy with respect to 
levels of fasting insulin, triglycerides, and low-den-
sity lipoprotein cholesterol as compared to carriers 
of the CC or CT genotype (123).
A recent study performed by Sheng et al. (124) sug-
gested that the -3186C>T SNP of gene encoding 
nicotinamide phosphoribosyltransferase (NAMPT) 
was signifi cantly associated with postprandial in-
sulin and total cholesterol levels in Chinese T2DM 
patients treated with repaglinide. Following the 
drug treatment, the elevated postprandial insulin 
levels as well as the total cholesterol levels in pa-
tients with CT genotype were signifi cantly lower 
than in T2DM patients with the CC and TT geno-
type of the -3186C>T polymorphism (124).
Conclusions
In conclusion, the evidence has been accumulat-
ing to show that pharmacogenetics/pharmacoge-
nomics has the potential to improve the manage-
ment of T2DM and the eff ective OAD prescribing. 
Several variants related to drug-metabolizing en-
zymes, drug-transporters, drug target, and diabe-
tes risk genes have been linked to interindividual 
diff erences in the OAD treatment outcomes. As 
summarized here, signifi cant pharmacogenetic 
evidence has demonstrated an association be-
tween specifi c gene polymorphisms and interindi-
vidual variability in OAD therapeutic and side ef-
fects. Identifi cation of drug-genotype interactions 
in pharmacogenetic studies of the OAD treatment 
might have clinical implications in the near future 
resulting in selection of more specifi c personalized 
therapy in T2DM. Although benefi ts from a per-
sonalized diabetes care are well established in pa-
tients with certain monogenic forms of diabetes, 
individualized treatment options in the more com-
mon polygenic forms of diabetes are also antici-
pated. However, it is also well understood that the 
diversity in drug eff ects cannot be explained by 
studying the genomic variations only and there 
are many potential barriers to the translation of 
pharmacogenetic fi ndings to the antidiabetic 
treatment. Particularly, epigenomic research that 
focuses on nongenomic modifi cations infl uencing 
gene expression, may expand the scope of phar-
macogenomics towards optimization of drug ther-
apy. Recently introduced “miRNA-pharmacoge-
nomics” that analyzes the polymorphisms in the 
miRNA regulatory pathway and its association with 
drug response, would also provide useful informa-
tion for personalized medicine. Since the pharma-
cogenetic associations in diabetes that have been 
reported to date have had limited impact on the 
individual treatments choice, the value of genetic 
information in guiding therapeutic decisions in 
T2DM treatment must be further tested in ade-
quately designed and rigorously conducted clini-
cal trials. With recent scientifi c and technological 
advances, pharmacogenomics has a great poten-
tial to yield therapeutic advances leading the way 
towards personalized diabetes care.
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